121. A method for treating a mammal in need of therapy by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent.

122. A method of claim 121 wherein active ingredient (a) is amlodipine besylate.

123. A method of claim 122 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

124. A method of claim 121 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

125. The method of claim 121 wherein active ingredients (a) and (b) are administered simultaneously.

126. The method of claim 121 wherein active ingredients (a) and (b) are administered sequentially in either order.

127. A method of treating a mammal which has been diagnosed as suffering from a condition or the risk of a condition which would benefit from therapy by the combined administration of the active ingredients designated as (a) and (b) below, and therefore

administration of both (a) and (b) has been prescribed, which comprises administering to said mammal so diagnosed and prescribed

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent.

128. A method of claim 127 wherein active ingredient (a) is amlodipine besylate.

129. A method of claim 128 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

130. A method of claim 127 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

131. The method of claim 127 wherein active ingredients (a) and (b) are administered simultaneously.

132. The method of claim 127 wherein active ingredients (a) and (b) are administered sequentially in either order.

133. A method of treating combined hypertension and hyperlipidemia in a mammal which has been examined for both hypertension and hyperlipidemia conditions by a medical practitioner and diagnosed as in need of therapy for said conditions by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent.

134. A method of claim 133 wherein active ingredient (a) is amlodipine besylate.

135. A method of claim 134 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

136. A method of claim 133 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

137. The method of claim 133 wherein active ingredients (a) and (b) are administered simultaneously.

138. The method of claim 133 wherein active ingredients (a) and (b) are administered sequentially in either order.

139. A method for preventing or reducing cardiac risk in a mammal which has been examined and diagnosed as having symptoms or risk factors for cardiac disease and in need of combined therapy to manage such risk by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) a prophylactically effective amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) a prophylactically effective amount of a second active ingredient (b), said second active ingredient being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent.

140. A method of claim 139 wherein active ingredient (a) is amlodipine besylate.

141. A method of claim 140 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

142. A method of claim 139 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

143. The method of claim 139 wherein active ingredients (a) and (b) are administered simultaneously.

144. The method of claim 139 wherein active ingredients (a) and (b) are administered sequentially in either order.

145. A method of treating angina in a mammal which has been examined for angina by a medical practitioner and diagnosed as in need of therapy for said angina by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent.

146. A method of claim 145 wherein active ingredient (a) is amlodipine besylate.

147. A method of claim 146 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

148. A method of claim 145 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

149. The method of claim 145 wherein active ingredients (a) and (b) are administered simultaneously.

150. The method of claim 145 wherein active ingredients (a) and (b) are administered sequentially in either order.

151. A method of treating atherosclerosis in a mammal which has been examined for atherosclerosis by a medical practitioner and diagnosed as in need of therapy for said atherosclerosis by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent.

152. A method of claim 151 wherein active ingredient (a) is amlodipine besylate

B1 cont

153. A method of claim 152 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

154. A method of claim 151 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

155. The method of claim 151 wherein active ingredients (a) and (b) are administered simultaneously.

156. The method of claim 151 wherein active ingredients (a) and (b) are administered sequentially in either order.

157. The method of claim 151 where the treatment results in slowing the progression of atherosclerotic plaques.

158. The method of claim 157 where the progression of atherosclerotic plaques is slowed in coronary arteries.

159. The method of claim 157 where the progression of atherosclerotic plaques is slowed in the carotid arteries.

160. The method of claim 157 wherein the progression of atherosclerotic plaques is slowed in the peripheral arterial system.

161. The method according to claim 151 wherein the treatment results in a regression of atherosclerotic plaque.

162. The method according to claim 161 wherein the regression of atheroscleotic plaques occurs in the coronary arteries.

163. The method according to claim 161 wherein the regression of atheroscleotic plaques occurs in the carotid arteries.

164. The method according to claim 161 wherein the regression of atheroscleotic plaques occurs in the peripheral arterial system.

165. A kit for achieving a therapeutic effect in a mammal which has been prescribed the joint administration of the active ingredients designated as (a) and (b) below, each active ingredient forming a portion of said kit, comprising in association

(1) a therapeutically effective amount of a first active ingredient (a), said first active ingredient being amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;

2) a therapeutically effective amount of a second active ingredient (b), said second active ingredient being atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and

(3) directions for the administration of active ingredients (a) and (b) in a manner to achieve the desired therapeutic effect.

166. A kit of claim 165 wherein active ingredient (a) is amlodipine besylate.

167. A kit of claim 166 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

168. A kit of claim 165 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

169. The kit of claim 165 where the therapeutic effect is antihypertensive and antihyperlipidemic.